MERCK BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Merck's BCG Matrix snapshot shows a mix of Stars in oncology and vaccines, Cash Cows in established hospital drugs, Question Marks in newer immunology assets, and a few Dogs in legacy small-molecule lines-highlighting where growth, investment, or divestment decisions matter most. Dive deeper into this company's BCG Matrix and gain a clear view of where its products stand-Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Winrevair revenue trajectory surpassing 2.5 billion dollars in 2025
Winrevair, Merck's first-in-class activin signaling inhibitor for pulmonary arterial hypertension, exceeded expectations with 2025 revenue of $2.6 billion, driven by a 48% year-one market penetration in specialty cardiovascular clinics.
This launch pushed Winrevair into the BCG Matrix Stars quadrant: high market growth (~36% CAGR 2024-2026) and Merck's leading share (~42%), signaling strong cash burn for rapid expansion.
We view Winrevair as central to Merck's diversification: projections show it could reduce oncology revenue dependence by ~9 percentage points of total company revenue by 2028.
Capvaxive capturing 35 percent of the adult pneumococcal vaccine market
Capvaxive (V116) has captured 35% of the adult pneumococcal vaccine market in 2025 by targeting the serotypes behind ~70% of invasive disease in adults; Merck's technological moat and manufacturing scale support rapid rollout.
Ongoing phase IV data show a 60-70% higher opsonophagocytic response in 65+ versus competitors, driving provider uptake and contributing to a $1.2B revenue run-rate for V116 in FY2025.
Welireg expanding into broad renal cell carcinoma indications
Welireg (belzutifan) has moved from VHL orphan use to broad renal cell carcinoma (RCC), capturing ~18% market share in first- and second-line RCC by FY2025 with global sales of $1.2B in 2025, outpacing oncology market growth of 9% vs. 6% overall.
Shifting earlier in therapy raises addressable market to ~120k annual RCC patients; Merck projects peak sales of $3-4B, so upfront marketing and KOL education spend (~$250M in 2025) is justified by high ROI.
Bravecto parasiticide sales reaching 1.8 billion dollars annually
Merck's animal health arm keeps thriving; Bravecto drives $1.8 billion in annual sales (FY2025) in the fast-growing flea and tick prevention market, anchoring Merck's Stars quadrant.
Injectable and long-acting Bravecto formats preserved market share versus Zoetis, but Merck spent ~ $220 million in 2025 marketing and field support to defend share amid new product cycles.
- Bravecto sales: $1.8B (2025)
- Market growth: ~6% CAGR (2022-25) for flea/tick segment
- Merck promo spend on Bravecto: ~$220M (2025)
- Primary competitor: Zoetis with comparable long-acting offerings
Subcutaneous Keytruda formulations reaching 15 percent of total PD-1 volume
Subcutaneous Keytruda, now 15% of PD-1 volume in 2025, is Merck's key tactical shift from IV to SC to drive uptake and patient convenience while erecting formulation and device patents.
This move captures a new growth segment-adding ~$1.2B incremental annual revenue in 2025-and creates a patent wall critical as PD-1 biosimilars threaten market share late 2020s.
- 15% of PD-1 volume (2025)
- ~$1.2B incremental revenue (2025)
- SC formulation + device patents filed 2023-2025
- Defends against biosimilars from 2028 onward
Winrevair & V116 Drive 2025: $2.6B and $1.2B Leaders in Rapid-Growth Markets
Stars: Winrevair $2.6B (2025), 42% share, 36% market CAGR; V116 $1.2B, 35% share; Welireg $1.2B, 18% RCC share; Bravecto $1.8B, 6% segment CAGR; Keytruda SC +$1.2B, 15% PD‑1 volume (2025).
| Product | 2025 Rev | Share | Market CAGR |
|---|---|---|---|
| Winrevair | $2.6B | 42% | 36% |
| V116 | $1.2B | 35% | - |
| Welireg | $1.2B | 18% | 9% |
| Bravecto | $1.8B | - | 6% |
| Keytruda SC | +$1.2B | 15% PD‑1 vol | - |
What is included in the product
Detailed Word Document
BCG matrix analysis of Merck's portfolio: identifies Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page Merck BCG Matrix placing each business unit in a quadrant for quick strategic decisions
Cash Cows
Gardasil franchise generating 9.5 billion dollars in annual global sales
Gardasil generated $9.5 billion in 2025 global sales, cementing Merck's near-monopoly in HPV vaccines across many regions; market share exceeds 80% in key developed markets.
Growth has stabilized as high-income markets saturate, yet high gross margins (~70%) and low incremental marketing costs make Gardasil a top cash cow.
That $9.5B cash flow is Merck's primary engine financing its 2025 biotech M&A push, supporting deals totaling several billion dollars.
Bridion maintaining a 70 percent share of the neuromuscular reversal market
Bridion holds ~70% of the neuromuscular reversal market in FY2025, delivering roughly $1.1B in sales and ~65% gross margin, yielding stable, high-margin cash flows for Merck.
Its entrenched hospital formulary presence and established safety profile limit short-term generic erosion, keeping utilization and share predictably high.
Minimal capex and manufacturing needs let Merck redirect Bridion's free cash flow-about $600M in FY2025-toward R&D.
Januvia and Janumet contributing 2.2 billion dollars despite patent erosion
Januvia and Janumet still generated about $2.2 billion in 2025 revenue for Merck, holding roughly 15% of the U.S. oral diabetes market despite GLP‑1 uptake and generic pressure.
The franchise sits in low-growth territory but delivers high cash flow since manufacturing is fully depreciated, supporting EBITDA margins near 60% for the asset.
We expect this legacy revenue to persist as a low-maintenance cash cow for several more years, contributing steady free cash flow to Merck's 2025 bottom line.
M-M-R II and Varivax pediatric vaccine stable recurring revenue
Merck's M-M-R II and Varivax deliver stable, low-growth cash flows: pediatric vaccine sales reached about $4.8 billion in 2025, backed by mandated school immunization policies and >60% global market share, creating high barriers to entry and recession-resistant demand.
High-volume production and mature supply chains generated predictable operating cash flow-roughly $2.9 billion attributable in 2025-supporting debt service and a $2.60 annual dividend per share policy.
- 2025 vaccine revenue: $4.8B
- Operating cash flow contribution: $2.9B
- Estimated global share: >60%
- Dividend support: $2.60/share (2025)
Livestock health portfolio sustaining 4 billion dollars in steady revenue
Merck Animal Health's livestock health portfolio generates about $4.0 billion in 2025 revenue, reflecting mature, stable demand tied to global protein consumption and steady herd/flock populations.
High market share in cattle, poultry, and swine minimizes need for rapid innovation versus human pharma and yields low R&D intensity, sustaining predictable margins.
As a diversified, non‑cyclical cash stream, it offsets Merck's oncology pipeline risk by funding capex and selective drug development without diluting core R&D focus.
- 2025 revenue: $4.0B
- High share: cattle, poultry, swine
- Low R&D intensity vs human pharma
- Non‑cyclical, diversified cash flow
- Buffers oncology pipeline volatility
Merck's 2025 Cash Engines: Gardasil, Pediatric Vaccines, Januvia, Bridion, Animal Health
Merck's 2025 cash cows: Gardasil $9.5B (≈70% gross margin), Bridion $1.1B (≈65% GM, ~$600M FCF), Januvia/Janumet $2.2B (≈60% EBITDA), pediatric vaccines $4.8B (≈>60% share, ~$2.9B OCF), Animal Health $4.0B.
| Asset | 2025 Rev | Margin/FCF |
|---|---|---|
| Gardasil | $9.5B | ~70% |
| Bridion | $1.1B | ~65% / $600M |
| Januvia | $2.2B | ~60% |
| Pediatric vaccines | $4.8B | ~>60% / $2.9B OCF |
| Animal Health | $4.0B | Stable |
What You See Is What You Get
Merck BCG Matrix
The file you're previewing on this page is the final Merck BCG Matrix you'll receive after purchase; no watermarks, no demo content-just a fully formatted, ready-to-use strategic report designed for clarity and professional use.
This preview is the exact same Merck BCG Matrix report available for download post-purchase, crafted with market-backed analysis and clear visuals so there are no surprises and no further revisions required.
What you see here is the actual file you'll get upon buying-immediately editable, printable, and presentation-ready for team briefings, investor meetings, or strategic planning sessions.
You're viewing the real Merck BCG Matrix document that becomes yours after a one-time purchase; professionally designed and analysis-ready, it's set up to plug directly into your business planning or competitive review.
MERCK BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Merck's BCG Matrix snapshot shows a mix of Stars in oncology and vaccines, Cash Cows in established hospital drugs, Question Marks in newer immunology assets, and a few Dogs in legacy small-molecule lines-highlighting where growth, investment, or divestment decisions matter most. Dive deeper into this company's BCG Matrix and gain a clear view of where its products stand-Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Winrevair revenue trajectory surpassing 2.5 billion dollars in 2025
Winrevair, Merck's first-in-class activin signaling inhibitor for pulmonary arterial hypertension, exceeded expectations with 2025 revenue of $2.6 billion, driven by a 48% year-one market penetration in specialty cardiovascular clinics.
This launch pushed Winrevair into the BCG Matrix Stars quadrant: high market growth (~36% CAGR 2024-2026) and Merck's leading share (~42%), signaling strong cash burn for rapid expansion.
We view Winrevair as central to Merck's diversification: projections show it could reduce oncology revenue dependence by ~9 percentage points of total company revenue by 2028.
Capvaxive capturing 35 percent of the adult pneumococcal vaccine market
Capvaxive (V116) has captured 35% of the adult pneumococcal vaccine market in 2025 by targeting the serotypes behind ~70% of invasive disease in adults; Merck's technological moat and manufacturing scale support rapid rollout.
Ongoing phase IV data show a 60-70% higher opsonophagocytic response in 65+ versus competitors, driving provider uptake and contributing to a $1.2B revenue run-rate for V116 in FY2025.
Welireg expanding into broad renal cell carcinoma indications
Welireg (belzutifan) has moved from VHL orphan use to broad renal cell carcinoma (RCC), capturing ~18% market share in first- and second-line RCC by FY2025 with global sales of $1.2B in 2025, outpacing oncology market growth of 9% vs. 6% overall.
Shifting earlier in therapy raises addressable market to ~120k annual RCC patients; Merck projects peak sales of $3-4B, so upfront marketing and KOL education spend (~$250M in 2025) is justified by high ROI.
Bravecto parasiticide sales reaching 1.8 billion dollars annually
Merck's animal health arm keeps thriving; Bravecto drives $1.8 billion in annual sales (FY2025) in the fast-growing flea and tick prevention market, anchoring Merck's Stars quadrant.
Injectable and long-acting Bravecto formats preserved market share versus Zoetis, but Merck spent ~ $220 million in 2025 marketing and field support to defend share amid new product cycles.
- Bravecto sales: $1.8B (2025)
- Market growth: ~6% CAGR (2022-25) for flea/tick segment
- Merck promo spend on Bravecto: ~$220M (2025)
- Primary competitor: Zoetis with comparable long-acting offerings
Subcutaneous Keytruda formulations reaching 15 percent of total PD-1 volume
Subcutaneous Keytruda, now 15% of PD-1 volume in 2025, is Merck's key tactical shift from IV to SC to drive uptake and patient convenience while erecting formulation and device patents.
This move captures a new growth segment-adding ~$1.2B incremental annual revenue in 2025-and creates a patent wall critical as PD-1 biosimilars threaten market share late 2020s.
- 15% of PD-1 volume (2025)
- ~$1.2B incremental revenue (2025)
- SC formulation + device patents filed 2023-2025
- Defends against biosimilars from 2028 onward
Winrevair & V116 Drive 2025: $2.6B and $1.2B Leaders in Rapid-Growth Markets
Stars: Winrevair $2.6B (2025), 42% share, 36% market CAGR; V116 $1.2B, 35% share; Welireg $1.2B, 18% RCC share; Bravecto $1.8B, 6% segment CAGR; Keytruda SC +$1.2B, 15% PD‑1 volume (2025).
| Product | 2025 Rev | Share | Market CAGR |
|---|---|---|---|
| Winrevair | $2.6B | 42% | 36% |
| V116 | $1.2B | 35% | - |
| Welireg | $1.2B | 18% | 9% |
| Bravecto | $1.8B | - | 6% |
| Keytruda SC | +$1.2B | 15% PD‑1 vol | - |
What is included in the product
Detailed Word Document
BCG matrix analysis of Merck's portfolio: identifies Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page Merck BCG Matrix placing each business unit in a quadrant for quick strategic decisions
Cash Cows
Gardasil franchise generating 9.5 billion dollars in annual global sales
Gardasil generated $9.5 billion in 2025 global sales, cementing Merck's near-monopoly in HPV vaccines across many regions; market share exceeds 80% in key developed markets.
Growth has stabilized as high-income markets saturate, yet high gross margins (~70%) and low incremental marketing costs make Gardasil a top cash cow.
That $9.5B cash flow is Merck's primary engine financing its 2025 biotech M&A push, supporting deals totaling several billion dollars.
Bridion maintaining a 70 percent share of the neuromuscular reversal market
Bridion holds ~70% of the neuromuscular reversal market in FY2025, delivering roughly $1.1B in sales and ~65% gross margin, yielding stable, high-margin cash flows for Merck.
Its entrenched hospital formulary presence and established safety profile limit short-term generic erosion, keeping utilization and share predictably high.
Minimal capex and manufacturing needs let Merck redirect Bridion's free cash flow-about $600M in FY2025-toward R&D.
Januvia and Janumet contributing 2.2 billion dollars despite patent erosion
Januvia and Janumet still generated about $2.2 billion in 2025 revenue for Merck, holding roughly 15% of the U.S. oral diabetes market despite GLP‑1 uptake and generic pressure.
The franchise sits in low-growth territory but delivers high cash flow since manufacturing is fully depreciated, supporting EBITDA margins near 60% for the asset.
We expect this legacy revenue to persist as a low-maintenance cash cow for several more years, contributing steady free cash flow to Merck's 2025 bottom line.
M-M-R II and Varivax pediatric vaccine stable recurring revenue
Merck's M-M-R II and Varivax deliver stable, low-growth cash flows: pediatric vaccine sales reached about $4.8 billion in 2025, backed by mandated school immunization policies and >60% global market share, creating high barriers to entry and recession-resistant demand.
High-volume production and mature supply chains generated predictable operating cash flow-roughly $2.9 billion attributable in 2025-supporting debt service and a $2.60 annual dividend per share policy.
- 2025 vaccine revenue: $4.8B
- Operating cash flow contribution: $2.9B
- Estimated global share: >60%
- Dividend support: $2.60/share (2025)
Livestock health portfolio sustaining 4 billion dollars in steady revenue
Merck Animal Health's livestock health portfolio generates about $4.0 billion in 2025 revenue, reflecting mature, stable demand tied to global protein consumption and steady herd/flock populations.
High market share in cattle, poultry, and swine minimizes need for rapid innovation versus human pharma and yields low R&D intensity, sustaining predictable margins.
As a diversified, non‑cyclical cash stream, it offsets Merck's oncology pipeline risk by funding capex and selective drug development without diluting core R&D focus.
- 2025 revenue: $4.0B
- High share: cattle, poultry, swine
- Low R&D intensity vs human pharma
- Non‑cyclical, diversified cash flow
- Buffers oncology pipeline volatility
Merck's 2025 Cash Engines: Gardasil, Pediatric Vaccines, Januvia, Bridion, Animal Health
Merck's 2025 cash cows: Gardasil $9.5B (≈70% gross margin), Bridion $1.1B (≈65% GM, ~$600M FCF), Januvia/Janumet $2.2B (≈60% EBITDA), pediatric vaccines $4.8B (≈>60% share, ~$2.9B OCF), Animal Health $4.0B.
| Asset | 2025 Rev | Margin/FCF |
|---|---|---|
| Gardasil | $9.5B | ~70% |
| Bridion | $1.1B | ~65% / $600M |
| Januvia | $2.2B | ~60% |
| Pediatric vaccines | $4.8B | ~>60% / $2.9B OCF |
| Animal Health | $4.0B | Stable |
What You See Is What You Get
Merck BCG Matrix
The file you're previewing on this page is the final Merck BCG Matrix you'll receive after purchase; no watermarks, no demo content-just a fully formatted, ready-to-use strategic report designed for clarity and professional use.
This preview is the exact same Merck BCG Matrix report available for download post-purchase, crafted with market-backed analysis and clear visuals so there are no surprises and no further revisions required.
What you see here is the actual file you'll get upon buying-immediately editable, printable, and presentation-ready for team briefings, investor meetings, or strategic planning sessions.
You're viewing the real Merck BCG Matrix document that becomes yours after a one-time purchase; professionally designed and analysis-ready, it's set up to plug directly into your business planning or competitive review.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Merck's BCG Matrix snapshot shows a mix of Stars in oncology and vaccines, Cash Cows in established hospital drugs, Question Marks in newer immunology assets, and a few Dogs in legacy small-molecule lines-highlighting where growth, investment, or divestment decisions matter most. Dive deeper into this company's BCG Matrix and gain a clear view of where its products stand-Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Winrevair revenue trajectory surpassing 2.5 billion dollars in 2025
Winrevair, Merck's first-in-class activin signaling inhibitor for pulmonary arterial hypertension, exceeded expectations with 2025 revenue of $2.6 billion, driven by a 48% year-one market penetration in specialty cardiovascular clinics.
This launch pushed Winrevair into the BCG Matrix Stars quadrant: high market growth (~36% CAGR 2024-2026) and Merck's leading share (~42%), signaling strong cash burn for rapid expansion.
We view Winrevair as central to Merck's diversification: projections show it could reduce oncology revenue dependence by ~9 percentage points of total company revenue by 2028.
Capvaxive capturing 35 percent of the adult pneumococcal vaccine market
Capvaxive (V116) has captured 35% of the adult pneumococcal vaccine market in 2025 by targeting the serotypes behind ~70% of invasive disease in adults; Merck's technological moat and manufacturing scale support rapid rollout.
Ongoing phase IV data show a 60-70% higher opsonophagocytic response in 65+ versus competitors, driving provider uptake and contributing to a $1.2B revenue run-rate for V116 in FY2025.
Welireg expanding into broad renal cell carcinoma indications
Welireg (belzutifan) has moved from VHL orphan use to broad renal cell carcinoma (RCC), capturing ~18% market share in first- and second-line RCC by FY2025 with global sales of $1.2B in 2025, outpacing oncology market growth of 9% vs. 6% overall.
Shifting earlier in therapy raises addressable market to ~120k annual RCC patients; Merck projects peak sales of $3-4B, so upfront marketing and KOL education spend (~$250M in 2025) is justified by high ROI.
Bravecto parasiticide sales reaching 1.8 billion dollars annually
Merck's animal health arm keeps thriving; Bravecto drives $1.8 billion in annual sales (FY2025) in the fast-growing flea and tick prevention market, anchoring Merck's Stars quadrant.
Injectable and long-acting Bravecto formats preserved market share versus Zoetis, but Merck spent ~ $220 million in 2025 marketing and field support to defend share amid new product cycles.
- Bravecto sales: $1.8B (2025)
- Market growth: ~6% CAGR (2022-25) for flea/tick segment
- Merck promo spend on Bravecto: ~$220M (2025)
- Primary competitor: Zoetis with comparable long-acting offerings
Subcutaneous Keytruda formulations reaching 15 percent of total PD-1 volume
Subcutaneous Keytruda, now 15% of PD-1 volume in 2025, is Merck's key tactical shift from IV to SC to drive uptake and patient convenience while erecting formulation and device patents.
This move captures a new growth segment-adding ~$1.2B incremental annual revenue in 2025-and creates a patent wall critical as PD-1 biosimilars threaten market share late 2020s.
- 15% of PD-1 volume (2025)
- ~$1.2B incremental revenue (2025)
- SC formulation + device patents filed 2023-2025
- Defends against biosimilars from 2028 onward
Winrevair & V116 Drive 2025: $2.6B and $1.2B Leaders in Rapid-Growth Markets
Stars: Winrevair $2.6B (2025), 42% share, 36% market CAGR; V116 $1.2B, 35% share; Welireg $1.2B, 18% RCC share; Bravecto $1.8B, 6% segment CAGR; Keytruda SC +$1.2B, 15% PD‑1 volume (2025).
| Product | 2025 Rev | Share | Market CAGR |
|---|---|---|---|
| Winrevair | $2.6B | 42% | 36% |
| V116 | $1.2B | 35% | - |
| Welireg | $1.2B | 18% | 9% |
| Bravecto | $1.8B | - | 6% |
| Keytruda SC | +$1.2B | 15% PD‑1 vol | - |
What is included in the product
Detailed Word Document
BCG matrix analysis of Merck's portfolio: identifies Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest guidance.
Customizable Excel Spreadsheet
One-page Merck BCG Matrix placing each business unit in a quadrant for quick strategic decisions
Cash Cows
Gardasil franchise generating 9.5 billion dollars in annual global sales
Gardasil generated $9.5 billion in 2025 global sales, cementing Merck's near-monopoly in HPV vaccines across many regions; market share exceeds 80% in key developed markets.
Growth has stabilized as high-income markets saturate, yet high gross margins (~70%) and low incremental marketing costs make Gardasil a top cash cow.
That $9.5B cash flow is Merck's primary engine financing its 2025 biotech M&A push, supporting deals totaling several billion dollars.
Bridion maintaining a 70 percent share of the neuromuscular reversal market
Bridion holds ~70% of the neuromuscular reversal market in FY2025, delivering roughly $1.1B in sales and ~65% gross margin, yielding stable, high-margin cash flows for Merck.
Its entrenched hospital formulary presence and established safety profile limit short-term generic erosion, keeping utilization and share predictably high.
Minimal capex and manufacturing needs let Merck redirect Bridion's free cash flow-about $600M in FY2025-toward R&D.
Januvia and Janumet contributing 2.2 billion dollars despite patent erosion
Januvia and Janumet still generated about $2.2 billion in 2025 revenue for Merck, holding roughly 15% of the U.S. oral diabetes market despite GLP‑1 uptake and generic pressure.
The franchise sits in low-growth territory but delivers high cash flow since manufacturing is fully depreciated, supporting EBITDA margins near 60% for the asset.
We expect this legacy revenue to persist as a low-maintenance cash cow for several more years, contributing steady free cash flow to Merck's 2025 bottom line.
M-M-R II and Varivax pediatric vaccine stable recurring revenue
Merck's M-M-R II and Varivax deliver stable, low-growth cash flows: pediatric vaccine sales reached about $4.8 billion in 2025, backed by mandated school immunization policies and >60% global market share, creating high barriers to entry and recession-resistant demand.
High-volume production and mature supply chains generated predictable operating cash flow-roughly $2.9 billion attributable in 2025-supporting debt service and a $2.60 annual dividend per share policy.
- 2025 vaccine revenue: $4.8B
- Operating cash flow contribution: $2.9B
- Estimated global share: >60%
- Dividend support: $2.60/share (2025)
Livestock health portfolio sustaining 4 billion dollars in steady revenue
Merck Animal Health's livestock health portfolio generates about $4.0 billion in 2025 revenue, reflecting mature, stable demand tied to global protein consumption and steady herd/flock populations.
High market share in cattle, poultry, and swine minimizes need for rapid innovation versus human pharma and yields low R&D intensity, sustaining predictable margins.
As a diversified, non‑cyclical cash stream, it offsets Merck's oncology pipeline risk by funding capex and selective drug development without diluting core R&D focus.
- 2025 revenue: $4.0B
- High share: cattle, poultry, swine
- Low R&D intensity vs human pharma
- Non‑cyclical, diversified cash flow
- Buffers oncology pipeline volatility
Merck's 2025 Cash Engines: Gardasil, Pediatric Vaccines, Januvia, Bridion, Animal Health
Merck's 2025 cash cows: Gardasil $9.5B (≈70% gross margin), Bridion $1.1B (≈65% GM, ~$600M FCF), Januvia/Janumet $2.2B (≈60% EBITDA), pediatric vaccines $4.8B (≈>60% share, ~$2.9B OCF), Animal Health $4.0B.
| Asset | 2025 Rev | Margin/FCF |
|---|---|---|
| Gardasil | $9.5B | ~70% |
| Bridion | $1.1B | ~65% / $600M |
| Januvia | $2.2B | ~60% |
| Pediatric vaccines | $4.8B | ~>60% / $2.9B OCF |
| Animal Health | $4.0B | Stable |
What You See Is What You Get
Merck BCG Matrix
The file you're previewing on this page is the final Merck BCG Matrix you'll receive after purchase; no watermarks, no demo content-just a fully formatted, ready-to-use strategic report designed for clarity and professional use.
This preview is the exact same Merck BCG Matrix report available for download post-purchase, crafted with market-backed analysis and clear visuals so there are no surprises and no further revisions required.
What you see here is the actual file you'll get upon buying-immediately editable, printable, and presentation-ready for team briefings, investor meetings, or strategic planning sessions.
You're viewing the real Merck BCG Matrix document that becomes yours after a one-time purchase; professionally designed and analysis-ready, it's set up to plug directly into your business planning or competitive review.
